Repetitive Levosimendan Infusion for Patients With Advanced Chronic Heart Failure

Summary

Repetitive levosimendan infusions for patients with advanced chronic heart failure (LeoDOR) A randomised, double-blind, placebo-controlled multicentre study with parallel group design. Mortality and rehospitalisation rates are high in the vulnerable phase following heart failure hospitalisation. Previous studies suggest that these events can be reduced by repeat infusions of levosimendan in patients with advanced heart failure.

Timeline

Start

2018-03-08

Primary completion

2019-04-01

Completion

2019-12-31

Drugs

Indications